TEVA PHARMACEUTICAL INDUSTRIES LIMITED Lease, Cost
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Lease, Cost of $136.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for the quarter ending 2019-12-31 was $47.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for the quarter ending 2019-09-30 was $46.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for the quarter ending 2019-06-30 was $39.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for the quarter ending 2019-03-31 was $46.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for fiscal 2025 was $136.00M, a 4.23% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for fiscal 2024 was $142.00M, a 2.16% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for fiscal 2023 was $139.00M, a 6.08% decline from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED lease, cost for fiscal 2022 was $148.00M, a 4.96% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $136.00M 10-K · filed 2026-02-03 | |||
| 2024-12-31 | $142.00M 10-K · filed 2026-02-03 | |||
| 2023-12-31 | $139.00M 10-K · filed 2026-02-03 | |||
| 2022-12-31 | $148.00M 10-K · filed 2025-02-05 | |||
| 2021-12-31 | $141.00M 10-K · filed 2024-02-12 | |||
| 2020-12-31 | $155.00M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $93.00M derived: sum of 2 quarters · filed 2022-02-09 | $132.00M derived: sum of 3 quarters · filed 2022-02-09 | $178.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $46.00M 10-Q · filed 2019-11-07 | $85.00M derived: sum of 2 quarters · filed 2019-11-07 | $131.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $39.00M 10-Q · filed 2019-08-07 | $85.00M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $46.00M 10-Q · filed 2019-05-02 |